Belatacept and long-term outcomes in kidney transplantation

New England Journal of Medicine

Volumn 374, Issue 26, 2016, Pages 2598-

  Meaney, Calvin J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BELATACEPT; CYCLOSPORIN; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; ABATACEPT; IMMUNOSUPPRESSIVE AGENT;

B LYMPHOCYTE; DEATH; DRUG ACTIVITY; DRUG EFFICACY; DRUG EXPOSURE; FOLLOW UP; GRAFT FAILURE; HUMAN; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LETTER; LONG-TERM OUTCOME; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; RISK; T LYMPHOCYTE; TREATMENT OUTCOME; GRAFT SURVIVAL; KIDNEY FAILURE, CHRONIC;

ABATACEPT; CYCLOSPORINE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION;

EID: 84976517931     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1602859     Document Type: Letter

References (5)

1. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and longterm outcomes in kidney transplantation. N Engl J Med 2016; 374:333-43.
2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46: 13-58.
3. Le Meur Y, Borrows R, Pescovitz MD, et al. Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of the Transplantation Society consensus meeting. Transplant Rev (Orlando) 2011; 25:58-64.
4. Grinyó JM, Ekberg H, Mamelok RD, et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009; 24: 2269-76.
5. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86:1043-51.